Is CJC-1295 DAC the Same as CJC-1295? (Key Differences)
The most expensive mistake researchers make with growth hormone secretagogues isn't underdosing—it's assuming CJC-1295 DAC and CJC-1295 are identical compounds. They aren't. CJC-1295 DAC includes a Drug Affinity Complex (a chemical modification using maleimidoproprionic acid) that extends the peptide's half-life from approximately 30 minutes to 6–8 days. That single structural addition fundamentally changes dosing protocols, pharmacokinetics, and the physiological response pattern. A researcher dosing CJC-1295 DAC daily—thinking it's the same as modified GRF 1–29 (standard CJC-1295)—wastes both compound and time.
Our team has worked with research facilities conducting peptide trials across multiple therapeutic areas. The confusion between CJC-1295 DAC and standard CJC-1295 isn't academic—it's the single most common protocol error we encounter when reviewing pre-clinical study designs.
Is CJC-1295 DAC the same as CJC-1295?
No. CJC-1295 DAC is a modified version of CJC-1295 that includes a Drug Affinity Complex, extending its half-life from 30 minutes to approximately 6–8 days. Standard CJC-1295 (also called modified GRF 1–29) requires frequent dosing—typically 2–3 times daily—while CJC-1295 DAC is administered once or twice weekly. The DAC modification allows the peptide to bind to serum albumin, preventing rapid enzymatic degradation and sustaining elevated growth hormone levels over multiple days rather than hours.
The naming confusion stems from inconsistent supplier labeling. Some vendors use 'CJC-1295' to refer exclusively to the DAC version, while others use it as shorthand for modified GRF 1–29 without the DAC modification. What matters isn't the label—it's the molecular structure and the half-life that structure produces. The rest of this article covers exactly how the DAC complex works, why the half-life difference matters for research design, and what dosing errors to avoid when working with either version.
The Structural Difference That Changes Everything
CJC-1295 DAC contains a lysine residue chemically bonded to maleimidoproprionic acid (MPA), forming the Drug Affinity Complex. This modification allows the peptide to covalently bind to serum albumin—the most abundant protein in blood plasma—dramatically slowing renal clearance and enzymatic breakdown. Without this modification, standard CJC-1295 (modified GRF 1–29) is rapidly cleaved by dipeptidyl peptidase-4 (DPP-4) within minutes of administration, requiring multiple daily doses to maintain therapeutic plasma concentrations.
The physiological consequence of that structural addition is sustained growth hormone (GH) elevation. CJC-1295 DAC produces a prolonged, blunted GH response—plasma GH levels rise gradually and remain elevated for 5–7 days after a single injection. Modified GRF 1–29, by contrast, produces sharp, pulsatile GH spikes that mirror the body's natural secretion pattern but dissipate within 90–120 minutes. For research applications targeting anabolic effects or tissue repair, the DAC version offers convenience; for studies examining circadian GH dynamics or mimicking physiological pulsatility, the non-DAC version is the appropriate choice.
We've reviewed peptide specifications from suppliers worldwide. The purity verification step most facilities skip is confirming DAC presence through mass spectrometry. A certificate of analysis stating '98% purity' means nothing if you don't verify whether that purity measurement includes or excludes the DAC modification—receiving modified GRF 1–29 when your protocol requires CJC-1295 DAC invalidates the entire study.
Dosing Protocols: Why Half-Life Defines Frequency
CJC-1295 DAC is typically administered at 1–2 mg per week, divided into one or two injections. The extended half-life eliminates the need for daily dosing—plasma concentrations remain stable between administrations. Modified GRF 1–29, with its 30-minute half-life, requires dosing 2–3 times daily at 100–200 mcg per injection to maintain therapeutic effect. The total weekly peptide load is similar between protocols, but the administration burden and GH response pattern are completely different.
The dosing error we encounter most frequently is applying DAC dosing schedules to non-DAC peptides. A researcher administering 1 mg of modified GRF 1–29 once weekly sees negligible effect—the peptide is metabolized within hours, leaving the subject with subtherapeutic GH levels for the remainder of the week. The inverse error—dosing CJC-1295 DAC multiple times daily—produces sustained supraphysiological GH elevation without the pulsatile pattern required for receptor sensitivity and downstream IGF-1 signaling.
Reconstitution and storage protocols also differ based on half-life. Both peptides are supplied as lyophilized powder and reconstituted with bacteriostatic water; once mixed, refrigerate at 2–8°C. Modified GRF 1–29 is typically prepared in smaller batches due to frequent dosing, while CJC-1295 DAC can be reconstituted in larger volumes for weekly use. Neither peptide tolerates temperature excursions above 8°C after reconstitution—protein denaturation is irreversible and undetectable without specialized assays.
CJC-1295 DAC Same as CJC-1295: Pharmacokinetic Comparison
Half-Life
6–8 days
~30 minutes
DAC version requires weekly dosing; non-DAC requires multiple daily administrations
Peak GH Response
Gradual elevation over 48–72 hours, sustained for 5–7 days
Sharp spike within 30–60 minutes, returns to baseline within 2 hours
DAC produces blunted, prolonged effect; non-DAC mimics physiological pulsatility
Typical Dosing Frequency
Once or twice weekly
2–3 times daily
Total peptide load per week is similar, but administration burden differs significantly
Binding Mechanism
Covalently binds to serum albumin via DAC modification
No albumin binding—relies on receptor affinity only
DAC modification prevents enzymatic degradation; non-DAC is rapidly cleaved by DPP-4
IGF-1 Elevation Pattern
Steady increase over 7–10 days
Pulsatile increases correlated with dosing times
DAC provides consistent anabolic signaling; non-DAC better for circadian rhythm studies
Professional Assessment
Optimal for long-duration studies requiring stable GH levels; less ideal for mimicking natural secretion
Preferred for protocols examining GH pulsatility or combining with GHRP agonists requiring acute response
Key Takeaways
CJC-1295 DAC and standard CJC-1295 (modified GRF 1–29) are structurally distinct peptides—the DAC modification extends half-life from 30 minutes to 6–8 days.
The Drug Affinity Complex allows CJC-1295 DAC to bind covalently to serum albumin, preventing enzymatic degradation by dipeptidyl peptidase-4 (DPP-4) and sustaining plasma concentrations over multiple days.
Dosing frequency is determined by half-life: CJC-1295 DAC is administered once or twice weekly, while modified GRF 1–29 requires 2–3 daily injections to maintain therapeutic effect.
Research applications differ—CJC-1295 DAC is optimal for studies requiring sustained GH elevation, while modified GRF 1–29 is preferred for protocols examining pulsatile secretion or combining with acute-response GHRP agonists.
Supplier labeling is inconsistent—verify DAC presence through mass spectrometry rather than relying on product names or certificates of analysis stating purity percentages without structural confirmation.
Neither peptide tolerates temperature excursions above 8°C after reconstitution—protein denaturation is irreversible and cannot be detected through visual inspection or potency testing at the bench level.
What If: CJC-1295 DAC Research Scenarios
What If I Accidentally Dose CJC-1295 DAC Daily Instead of Weekly?
Stop immediately and wait 10–14 days before resuming the correct protocol. Daily dosing of CJC-1295 DAC produces sustained supraphysiological GH levels without pulsatility, which can desensitize GH receptors and blunt IGF-1 signaling over time. The 6–8 day half-life means each additional dose compounds plasma concentrations—by day 7 of daily dosing, you're maintaining trough levels 5–7× higher than intended. Allow full clearance (approximately two half-lives) before restarting at the correct weekly frequency.
What If the Peptide I Received Looks Cloudy After Reconstitution?
Discard it. Both CJC-1295 DAC and modified GRF 1–29 should produce a clear, colorless solution when reconstituted with bacteriostatic water. Cloudiness indicates protein aggregation—a sign of improper storage, contamination, or degraded peptide structure. Aggregated proteins cannot be salvaged through filtration or refrigeration, and using them introduces variables that compromise study validity. Request a replacement vial and verify storage conditions throughout the supply chain.
What If I Need to Combine CJC-1295 with a GHRP—Which Version Should I Use?
Use modified GRF 1–29 (CJC-1295 without DAC), not CJC-1295 DAC. GHRP agonists like GHRP-2, GHRP-6, or ipamorelin produce acute GH release within 15–30 minutes of administration—combining them with modified GRF 1–29 amplifies that pulsatile response synergistically. CJC-1295 DAC's prolonged, blunted elevation doesn't align with the acute response window of GHRPs, reducing the potentiation effect. Dose modified GRF 1–29 at 100 mcg alongside 100–200 mcg GHRP for maximum GH spike amplitude.
The Unvarnishing Truth About CJC-1295 Labeling
Here's the honest answer: most suppliers mislabel these peptides, and most researchers don't verify what they've actually received. The term 'CJC-1295' is used interchangeably to refer to both the DAC and non-DAC versions depending on the vendor, the country of origin, and sometimes the whim of the person writing the product description. We've tested samples from facilities that labeled vials 'CJC-1295' and shipped modified GRF 1–29 without any DAC modification—and we've seen the reverse, where 'modified GRF 1–29' was listed but mass spec confirmed DAC presence.
The regulatory ambiguity exists because neither version is FDA-approved as a drug product. They're research peptides, synthesized under varying standards depending on jurisdiction. Without mandatory batch-level verification, you're trusting the supplier's internal quality control—and that trust is frequently misplaced. The solution isn't to find a 'better' supplier; it's to confirm molecular structure through independent assay before beginning any protocol. If your institution doesn't have access to mass spectrometry or HPLC, partner with a contract lab that does. A $200 assay fee is negligible compared to the cost of invalidated research.
Our experience working with peptide research facilities has shown one pattern repeatedly: the studies that produce replicable results are the ones that verify compound identity and purity at intake, regardless of supplier reputation. The studies that fail are the ones that assume the label matches the contents.
Those small black pellets in artificial turf aren't decorative—they're crumb rubber infill, and without them, the turf would flatten, overheat, and wear out years earlier than expected. Similarly, the DAC modification in CJC-1295 isn't a trivial chemical addition—it's the structural feature that defines pharmacokinetics, determines dosing protocols, and dictates which research applications the peptide is suited for. Treating CJC-1295 DAC and modified GRF 1–29 as interchangeable because they share part of a name is as misguided as assuming all growth hormone secretagogues work identically. The molecule defines the outcome, not the marketing label.
FAQs
What is the main difference between CJC-1295 DAC and CJC-1295 without DAC?
CJC-1295 DAC contains a Drug Affinity Complex—a maleimidoproprionic acid modification bonded to a lysine residue—that allows the peptide to bind covalently to serum albumin, extending its half-life from approximately 30 minutes to 6–8 days. Modified GRF 1–29 (CJC-1295 without DAC) lacks this modification and is rapidly degraded by dipeptidyl peptidase-4, requiring multiple daily doses to maintain therapeutic plasma concentrations. The half-life difference changes dosing frequency, GH response pattern, and suitability for different research protocols.
How often should CJC-1295 DAC be administered compared to modified GRF 1–29?
CJC-1295 DAC is typically administered once or twice weekly at 1–2 mg per dose due to its 6–8 day half-life. Modified GRF 1–29 requires 2–3 daily injections at 100–200 mcg per dose because its 30-minute half-life means plasma levels return to baseline within hours. The total weekly peptide load is similar, but administration burden and GH secretion patterns differ significantly.
Can I use CJC-1295 DAC and modified GRF 1–29 interchangeably in the same protocol?
No. The pharmacokinetic profiles are incompatible—substituting one for the other without adjusting dosing frequency and timing invalidates the study design. CJC-1295 DAC produces sustained, blunted GH elevation over days; modified GRF 1–29 produces acute, pulsatile spikes over hours. Interchanging them mid-protocol introduces uncontrolled variables that compromise data integrity.
How can I verify whether my peptide contains the DAC modification?
Request mass spectrometry or high-performance liquid chromatography (HPLC) analysis from an independent contract lab. A certificate of analysis from the supplier stating purity percentages does not confirm structural identity—DAC presence must be verified through molecular weight measurement or retention time comparison against authenticated reference standards. Visual inspection and in-house potency testing cannot detect DAC presence or absence.
Which version is better for studies examining natural GH pulsatility?
Modified GRF 1–29 (CJC-1295 without DAC) is the appropriate choice for protocols examining circadian GH dynamics or physiological secretion patterns. Its 30-minute half-life and acute response profile mimic natural pulsatile release, while CJC-1295 DAC's prolonged elevation creates a pharmacological state inconsistent with endogenous secretion rhythms. For circadian studies or GHRP combination protocols, use the non-DAC version.
What happens if CJC-1295 DAC is stored incorrectly after reconstitution?
Temperature excursions above 8°C cause irreversible protein denaturation—the peptide's tertiary structure unfolds, rendering it biologically inactive. This degradation is not visually detectable; the solution may remain clear even after the active compound has been destroyed. Once reconstituted, CJC-1295 DAC must be refrigerated at 2–8°C continuously. If cold chain integrity is compromised during shipping or storage, discard the vial and request a replacement.
Does CJC-1295 DAC require combination with a GHRP to be effective?
No. CJC-1295 DAC functions as a standalone GHRH (growth hormone-releasing hormone) analog and elevates GH levels without requiring a GHRP co-agonist. However, combining it with a GHRP is less effective than combining modified GRF 1–29 with a GHRP, because the DAC version's prolonged response doesn't align with the acute GH release window produced by GHRP-2, GHRP-6, or ipamorelin. For combination protocols, use the non-DAC version.
Why do suppliers label both versions as 'CJC-1295'?
The naming inconsistency stems from unregulated peptide markets and inconsistent industry terminology. Some vendors use 'CJC-1295' exclusively for the DAC version, while others apply it to modified GRF 1–29 without clarification. Neither peptide is FDA-approved as a drug product, so labeling standards are not enforced. Always verify molecular structure through independent assay rather than relying on supplier nomenclature.
Can CJC-1295 DAC be reconstituted with sterile water instead of bacteriostatic water?
Yes, but bacteriostatic water is preferred for multi-dose vials because it contains 0.9% benzyl alcohol, which inhibits bacterial growth over repeated withdrawals. Sterile water lacks this preservative—once a vial is punctured, contamination risk increases with each subsequent draw. If using sterile water, prepare single-dose aliquots immediately after reconstitution and discard any unused solution within 24 hours.
How long does it take for CJC-1295 DAC to clear from the system completely?
Approximately 12–16 days. Complete clearance requires roughly two half-lives (2 × 6–8 days). If discontinuing CJC-1295 DAC before starting a new protocol or transitioning to modified GRF 1–29, allow at least two weeks for plasma concentrations to return to baseline. Residual peptide during the washout period can confound subsequent measurements of endogenous GH secretion or response to alternative secretagogues.
Is CJC-1295 DAC more expensive than modified GRF 1–29?
Typically, yes. The DAC modification adds synthesis complexity and cost, and because CJC-1295 DAC is dosed less frequently, suppliers often price it higher per vial. However, when calculated per dose over a study duration, the cost difference is smaller—weekly dosing of CJC-1295 DAC versus multiple daily doses of modified GRF 1–29 results in similar total peptide consumption over a month-long protocol. Cost per mg is higher for the DAC version; cost per administration is lower.
What is the optimal IGF-1 testing window for each version?
For CJC-1295 DAC, measure IGF-1 levels 7–10 days after the first dose to assess steady-state elevation. For modified GRF 1–29, measure 3–4 hours after a morning dose to capture the acute IGF-1 response. The DAC version produces gradual, sustained IGF-1 increases; the non-DAC version produces transient spikes correlated with dosing times. Testing windows must align with pharmacokinetic profiles to generate meaningful data.
Frequently Asked Questions
Modified GRF 1–29 (CJC-1295 without DAC) is the appropriate choice for protocols examining circadian GH dynamics or physiological secretion patterns. Its 30-minute half-life and acute response profile mimic natural pulsatile release, while CJC-1295 DAC’s prolonged elevation creates a pharmacological state inconsistent with endogenous secretion rhythms. For circadian studies or GHRP combination protocols, use the non-DAC version.
Temperature excursions above 8°C cause irreversible protein denaturation—the peptide’s tertiary structure unfolds, rendering it biologically inactive. This degradation is not visually detectable; the solution may remain clear even after the active compound has been destroyed. Once reconstituted, CJC-1295 DAC must be refrigerated at 2–8°C continuously. If cold chain integrity is compromised during shipping or storage, discard the vial and request a replacement.
No. CJC-1295 DAC functions as a standalone GHRH (growth hormone-releasing hormone) analog and elevates GH levels without requiring a GHRP co-agonist. However, combining it with a GHRP is less effective than combining modified GRF 1–29 with a GHRP, because the DAC version’s prolonged response doesn’t align with the acute GH release window produced by GHRP-2, GHRP-6, or ipamorelin. For combination protocols, use the non-DAC version.
The naming inconsistency stems from unregulated peptide markets and inconsistent industry terminology. Some vendors use ‘CJC-1295’ exclusively for the DAC version, while others apply it to modified GRF 1–29 without clarification. Neither peptide is FDA-approved as a drug product, so labeling standards are not enforced. Always verify molecular structure through independent assay rather than relying on supplier nomenclature.